Steven Freeman, MD
Internal Medicine · Easley, SCNPI 1538290374
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 756 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 756 payments — averaging $13.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$858
- Lilly USA, LLC$702
- Amgen$628
- Pfizer$598
- plus $5K from 50 others
What the payments were for
- Food & beverage$10,250100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,261 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $271,436 |
| OzempicSemaglutide | 80 | $92,028 |
| MounjaroTirzepatide | 76 | $84,709 |
| EliquisApixaban | 70 | $62,458 |
| Repatha SureclickEvolocumab | 74 | $46,491 |
| JanuviaSitagliptin Phosphate | 40 | $44,787 |
| JardianceEmpagliflozin | 31 | $31,922 |
| Risperdal ConstaRisperidone Microspheres | 13 | $30,156 |
| FarxigaDapagliflozin Propanediol | 27 | $28,185 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $26,208 |
| MyrbetriqMirabegron | 36 | $26,178 |
| TrulicityDulaglutide | 19 | $20,700 |
| LinzessLinaclotide | 31 | $19,974 |
| SomaCarisoprodol | 11 | $15,859 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $14,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $702 | $105,40995 claims |
| Novo NordiskOzempic, Rybelsus | $1,126 | $101,88992 claims |
| PfizerEliquis | $598 | $62,45870 claims |
| MerckJanuvia | $103 | $44,78740 claims |
| Johnson & JohnsonRisperdal Consta, Xarelto | $169 | $42,05625 claims |
| Boehringer IngelheimJardiance | $86 | $31,92231 claims |
| AstraZenecaFarxiga | $858 | $28,18527 claims |
| AbbVieLinzess, Synthroid | $1,547 | $26,520119 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $166 | $26,20832 claims |
| Astellas Pharma US IncMyrbetriq | $79 | $26,17836 claims |
| GSKTrelegy Ellipta | $241 | $7,81813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Easley
- David ChangEasley$13K
- Roger BoatwrightEasley$13K
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
- Bruce GrayGreenville$111K
- Leonard AlsfeldCharleston$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.